A Study of MTPS9579A in Participants With Refractory Chronic Spontaneous Urticaria

Summary

This pilot and dose-ranging study will evaluate the efficacy, safety, and pharmacokinetics of MTPS9579A compared with placebo in participants with chronic spontaneous urticaria (CSU) refractory to antihistamines. This study comprises two parts. In Part 1, participants will be randomized to receive MTPS9579A or placebo. On the basis of positive results from Part 1, a dose-ranging Part 2 may be opened, where participants will be randomized to receive one of four MTPS9579A doses or placebo.

Timeline

Start

2022-07-31

Primary completion

2024-07-31

Completion

2024-08-31

Outcome

Outcome not reported

Stopped (Business): “Development of MTPS9579A was terminated for strategic/business reasons.”

Drugs

Indications